Sebastien Bolze Selected Research

2- chloro- 3- (1- hydroxy- 5,6,7,8- tetrahydronaphthalen- 2- yl)- 6- oxo- 5- phenyl- 7H- thieno)(2,3- b)pyridin- 4- olate potassium

1/2022	Direct AMPK Activation Corrects NASH in Rodents Through Metabolic Effects and Direct Action on Inflammation and Fibrogenesis.
12/2021	Pharmacodynamic effects of direct AMP kinase activation in humans with insulin resistance and non-alcoholic fatty liver disease: A phase 1b study.
11/2021	Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sebastien Bolze Research Topics

Disease

3	Non-alcoholic Fatty Liver Disease 01/2022 - 11/2021
3	Insulin Resistance 01/2022 - 11/2021
2	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2022 - 12/2021
2	Inflammation (Inflammations) 01/2022 - 11/2021
1	Dyslipidemias (Dyslipidemia) 01/2022
1	Fatty Liver 12/2021
1	Overweight 12/2021
1	Alcoholic Fatty Liver 11/2021
1	Type 2 Diabetes Mellitus (MODY) 11/2021

Drug/Important Bio-Agent (IBA)

3	2- chloro- 3- (1- hydroxy- 5,6,7,8- tetrahydronaphthalen- 2- yl)- 6- oxo- 5- phenyl- 7H- thieno)(2,3- b)pyridin- 4- olate potassiumIBA 01/2022 - 11/2021
2	Adenylate KinaseIBA 12/2021 - 11/2021

Therapy/Procedure

1	Therapeutics 01/2022